Categories Other Industries

New flu vaccine brings Novavax back to life

Novavax shares skyrocketed after the company’s latest study into its flu vaccine offered promising results. The company’s vaccine for flu, NanoFlu, generated stronger results when compared to the standard vaccines that are currently available.

The Gaithersburg, Maryland-based company had a tumultuous journey throughout 2017 after it witnessed a dramatic failure of its closely watched vaccine for respiratory infection. Though the company officials were quite confident about its success, investors started losing faith in this stock over rising concerns of its sustainability. This soon led way to takeover rumors.

Picture for representation

NanoFlu has now forced investors to change their opinion about this company.

Novavax claims that NanoFlu was almost 47-64% more effective against different strains of the nastiest H3N2, when compared to the standard flu vaccines.

Rivals Sanofi and GlaxoSmithKline have already developed their own flu vaccines and have started marketing them. However, Novavax claims that NanoFlu was almost 47-64% more effective against different strains of the nastiest H3N2, when compared to the standard flu vaccines. This marks a big achievement for Novavax, because several articles from various medical journals have highlighted how the other vaccines have been less effective against the swine flu virus.

If NanoFlu hits the right targets, investors may eventually see buyout rumors fading. The company plans to kick-start its Phase 2 trial for NanoFlu vaccine during the third quarter of this year.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top